Corient Private Wealth
CRSP icon

Corient Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Corient Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
33,841
-970
-3% -$51.1K ﹤0.01% 1443
2026
Q1 		$1.66M Buy
34,811
+30,245
+662% +$1.6M ﹤0.01% 1363
2025
Q4 		$239K Sell
4,566
-3,540
-44% -$212K ﹤0.01% 2329
2025
Q3 		$525K Buy
8,106
+3,387
+72% +$194K ﹤0.01% 1768
2025
Q2 		$230K Buy
+4,719
New +$183K ﹤0.01% 2151
2025
Q1 		– Sell
-8,827
Closed -$347K – 2320
2024
Q4 		$347K Sell
8,827
-365
-4% -$17.2K ﹤0.01% 1816
2024
Q3 		$432K Buy
9,192
+992
+12% +$50.3K ﹤0.01% 1820
2024
Q2 		$443K Sell
8,200
-658
-7% -$38.1K ﹤0.01% 1712
2024
Q1 		$604K Buy
8,858
+58
+0.7% +$4.15K ﹤0.01% 1539
2023
Q4 		$551K Sell
8,800
-546
-6% -$30.2K ﹤0.01% 1573
2023
Q3 		$424K Buy
9,346
+1,699
+22% +$87.7K ﹤0.01% 1576
2023
Q2 		$429K Sell
7,647
-232
-3% -$13.2K ﹤0.01% 1526
2023
Q1 		$356K Buy
7,879
+707
+10% +$34.3K ﹤0.01% 1524
2022
Q4 		$292K Buy
+7,172
New +$380K ﹤0.01% 1345

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Corient Private Wealth's CRSP Position: Q2 2026 in Review

Corient Private Wealth reduced its CRISPR Therapeutics (CRSP) stake by 2.8% in Q2 2026, selling an estimated $51.1K and leaving 33,841 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

Corient Private Wealth first reported a position in CRSP in Q4 2022 and has held it in 14 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Corient Private Wealth held 33,841 shares of CRISPR Therapeutics worth $1.85M as of Q2 2026.
  • Corient Private Wealth sold 970 CRISPR Therapeutics shares in Q2 2026, an estimated $51.1K.
  • CRISPR Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1443 holding.
  • Corient Private Wealth first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.